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Localized scleroderma is a rare disease, characterized by sclerotic lesions. A variety of presentations have been described, with
diﬀerent clinical characteristics and speciﬁc prognosis. In scleroderma en coup de sabre (LScs) the atrophic lesion in frontoparietal
area is the disease hallmark. Skin and subcutaneous are the mainly aﬀected tissues, but case reports of muscle, cartilage, and
bone involvement are frequent. These cases pose a diﬃcult diﬀerential diagnosis with Parry-Romberg syndrome. Once considered
an exclusive cutaneous disorder, the neurologic involvement present in LScs has been described in several case reports. Seizures
are most frequently observed, but focal neurologic deﬁcits, movement disorders, trigeminal neuralgia, and mimics of hemiplegic
migraines have been reported. Computed tomography and magnetic resonance imaging have aided the characterization of central
nervous system lesions, and cerebral angiograms have pointed to vasculitis as a part of disease pathogenesis. In this paper we
describe the clinical and radiologic aspects of neurologic involvement in LScs.
1.Introduction
Scleroderma is a rare disease of unknown etiology, charac-
terized by thickening and hardening of skin resulting from
increasedcollagenproduction.Thetermincludesavarietyof
diseases, from localized scleroderma (LS) to systemic sclero-
sis.LSistraditionallyconsideredtobelimitedtoskin,subcu-
taneoustissue,underlyingbone,and,incraniofacialsubtype,
nervous system involvement [1]. Recent studies, however,
have described malaise, fatigue, arthralgia, and myalgia in
morphea. Moreover, rheumatologic, ophthalmologic and
neurologic symptoms and signs have been described in up to
20%ofthepatientswithLS.BasedontheseﬁndingsLSought
to be diﬀerentiated from systemic sclerosis by the absence of
sclerodactylya, Raynaud’s phenomenon, and capillaroscopic
abnormalities [1].
LS incidence ranges from 0.4 to 2.7 per 100,000 people
[2]. Although present in all races, the prevalence among
Caucasians is increased, summing up 72 to 82% of the
patients [2]. Females are primarily aﬀected [1], and a similar
distribution between children and adults occurs [1, 3].
Disease incidence peaks in the ﬁfth decade of life in adults,
whereas 90% of children are diagnosed between 2 and 14
years of age [1, 3–5].
Linear scleroderma en coup de sabre (LCsc) is a rare
subset of LS. The typical presentation aﬀects frontoparietal
region, and the mean age of onset is around 13 years
old [1]. In this paper, clinical presentation of LScs and its
neurological involvement are described.
2. Pathogenesis
Skin pathogenesis seems to be similar between LScs, LS, and
systemic sclerosis, although not fully understood [1, 6–8].
Clinical and pathological data support the hypothesis that
vasculature is the primary target in LS [6, 7, 9]. Early
skin biopsies revealed damaged endothelial cells preceding
the development of ﬁbrosis by months to years. Increased
vascular permeability is associated with mononuclear cell
inﬁltration, leading to perivascular inﬂammatory cell inﬁl-
trates, vascular intimal thickening, and vessel narrowing [8].
Gradually, the vessels lose their elasticity; media and2 Autoimmune Diseases
Table 1: Localized scleroderma classiﬁcation.
Classiﬁcation Subtypes Characteristic lesions Tissues involved Main Site
Circumscribed morphea
Superﬁcial variant Oval lesions Limited to epidermis and dermis Trunk
Deep variant Oval lesions
Deep indurations. Dermis and
subcutaneous tissue involved.
Variable muscle and fascia
involvement
Trunk
Linear morphea
(linear scleroderma)
Trunk/limb variant Linear indurations Dermis and subcutaneous tissue
(may involve muscle and bone) Trunk/limb
Head variant
(en coup de sabre) Linear indurations
Dermis of the frontoparietal area
(may involve muscle, bone, and
central nervous system)
Face and scalp
Parry-Romberg
syndrome
Dermis, subcutaneous tissue,
muscle, cartilage, and bone Unilateral face
Generalized morphea Four or more indurated
plaques >3cmeach
Usually limited to the dermis and
rarely involves subcutaneous tissue
Diﬀuse
(no face and hand)
Pansclerotic morphea Circumferential
involvement
Epidermis, dermis, subcutaneous
tissue, muscle and bone Limbs
Mixed variant morphea Combination of 2 or more previous
subtypes
adventitia become ﬁbrotic and more prone to small-artery
occlusion. The latter is further exacerbated by thrombotic
events driven by platelets activation, resulting in ﬁbrosis and
end-organ damage [8].
The inciting event for microvascular damage remains
unknown. Preceding trauma has been observed as initial
event in pediatric population [10, 11]. Previous infection,
particularly due to Borrelia burgdorferi, has been implicated
in Europe and Japan, but not conﬁrmed in the United States
[12,13].Geneticsparticipationinpathogenesisappearstobe
relativelyweak,sinceonlya4.7%concordancebetweentwins
hasbeenobserved[14]andfamilystudiesrevealedonly1.6%
frequency among ﬁrst-degree relatives [8, 15]. However,
several groups have identiﬁed polymorphisms in potential
candidate genes involved in immune regulation, such as
BANK1, C8orﬂ3-BLK, IL-23R, IRF5, STAT4, TBX21, and
TNFSF4, which may underlie the pathogenesis of systemic
sclerosis [8, 16]. Intriguingly, many of these polymorphisms
are shared with other rheumatic diseases, such as systemic
lupus erythematosus.
More than 1800 genes are diﬀerentially expressed in scle-
roderma skin compared to healthy controls; however anal-
ysis of visually unaﬀected skin reveals a similar gene expres-
sion as diseased skin [17, 18]. Altered gene expression is
mapped to ﬁbroblasts, endothelial, epithelial, smooth mus-
cle, T, and B cells [8]. Recently, Gardner et al. have found
signiﬁcant gene-expression signature in systemic sclerosis
patients, which has been mapped to TGF-β and WNT sig-
naling pathways, the production of extracellular matrix pro-
teins and CCN family proteins [18].
Pathogenesis of CNS involvement in LScs is due to per-
ivascular inﬁltrate and vasculitis [9, 19, 20]; however biopsy
is not routinely done and histological ﬁndings are available
only for patients with severe neurological ﬁndings. Gliosis,
suggesting chronic inﬂammatory process, leptomeningeal
band-like sclerosis,and thickened blood vessels’ walls,aswell
as intraparenchymal calciﬁcation, have also been described
in the few available studies [9, 19, 20].
To sum up, available data suggests a complex pathogen-
esis of scleroderma, in which blood vessels, the immune sys-
tem,andextracellularmatrixareaﬀectedandmaycontribute
to the development of the disease.
3. ClinicalPresentation
Ivory-colored, sclerotic lesions, with violaceous borders,
characterize LS. Number and distribution of lesions vary, as
well as their extent. These characteristics and tissue involve-
ment (dermis, subcutaneous tissue, fascia, and muscle) de-
termine the localized scleroderma classiﬁcation (Table 1)[ 1,
21].
LScs presents in a band-like fashion on the frontoparietal
scalp and forehead. Alopecia is common and many times is
the patient’s main concern. Skin lesions may extend to the
nose, cheek, chin, and neck [8, 22, 23] and usually have an
active stage lasting 2–5 years [24, 25]. Muscle, cartilage, and
bone lesions incur in facial atrophy: in this scenario, Parry-
Romberg syndrome (PRS) must be considered a diﬀerential
diagnosis. Up to 28% of patients having LScs manifests PRS
features,suchasaunilateralslowlyprogressiveatrophyofthe
face. PRS commonly aﬀects dermatomes of trigeminal nerve.
Skin, soft tissue muscles, and underlying bone structures are
involved [26]. Skin hyperpigmentation and discoloration
and hairless patches can be present. Many authors postulate
that LScs and PRS are clinical variants of the same disease.
Arguments for PRS inclusion on the spectrum of LS
disorders are compelling. LScs and PRS coexist in 20–37% of
the patients with LScs diagnosis, and both conditions have
similar age of onset and disease course [27]. Furthermore,
dermatologic ﬁndings in PRS are sometimes indistinguish-
able from those of LS [27]. However, some authors still
consider them as diﬀerent entities, since PRS does not alwaysAutoimmune Diseases 3
Table 2: Clinical aspects of linear scleroderma en coup de sabre
(LScs) and Parry-Romberg syndrome (PRS).
LScs PRS
Skin Induration and
thickening Not aﬀected
Initial site Forehead and scalp Cheek and nose
Spreading pattern
Usually does not
spread below the
forehead
Usually aﬀects
lower face
Occasionally aﬀects
nose, cheek, chin, and
neck
Usually
restricted to one
side
Occasionally bilateral
Systemic involvement Yes No
Intracranial involvement Yes Yes
have skin thickening [28–30] and the hemifacial atrophy oc-
curring in PRS is usually more prominent [25]( Table 2).
The diagnosis is clinical and based on characteristic cuta-
neous and soft tissue ﬁndings [6, 24, 25]. Currently no diag-
nostic laboratory tests exist. Nonetheless, 37–50% of the pa-
tients may present a positive ANA test (homogenousor spec-
kled patterns) [2, 6, 24], as well as anti-single-stranded-DNA
antibodies [5, 31, 32]. Antinucleosome antibodies, soluble
interleukine-2 receptor, and, recently, antiagalactosyl immu-
noglobulin G antibodies have been reported in LS [33–35].
In some patients, autoantibody may be present even before
the disease manifestation and patients with Scl-70, anticen-
tromere, Ro/La, or U1RNP antibodies should be followed
closely, as systemic disease might ensue [6].
4. Neurologic Involvement
LScs has been associated with a variety of neurologic
abnormalities and typically is preceded by the development
of cutaneous disease by months to years [8, 31, 36, 37].
Nervous system involvement is usually not correlated to
skin activity and may present years after the disease initial
symptomatology[37].In16%ofcases,neurologicsymptoms
predate the cutaneous manifestations [27].
Neurological symptoms and signs in LScs are protean
and include epilepsy [8, 38, 39], headache [27, 40], focal
neurologic deﬁcits, and movement disorders [27, 31, 36, 41,
42], as well as neuropsychiatric symptom and intellectual
deterioration [43–45].
4.1. Epilepsy. Epilepsy is a frequently reported manifestation
in LScs. An analysis of 54 patients with LScs or PRS has
revealed a prevalence of 73% of seizures, 33% of them
refractory to antiepileptic medications [27]. Complex partial
seizures have been reported most frequently, followed by
tonic-clonic, absence seizures, as well as status epilepticus
[9, 38, 39]. Electroencephalography analyses show abnor-
malities in the majority of patients. Some authors advocate
that brain lesions of LS are more epileptogenic than those of
other autoimmune disorders [27].
4.2. Focal Neurologic Deﬁcits and Movement Disorders. Focal
neurologic deﬁcits and movement disorders secondary to
brain lesions have also been described, but seem to be
relatively uncommon [27, 36, 41]. In an analysis of 54
patients, focal neurological deﬁcits were described in 11%
of patients at presentation and in 35% of patients overall
[27]. While facial palsy and extraocular movement disorder
may be due to cutaneous involvement, trigeminal neuralgia
[31] and masticatory spasms [42] are considered primary
neurologic involvement.
4.3. Other Neurological Findings. Around 35% of LScs pa-
tients refer headache, which is usually associated with other
neurologic complaints [27]. Few studies have investigated
headache subtype, but migraines and mimics of hemiplegic
migraine seem to be more prevalent [27, 40].
Neuropsychiatric symptoms have been described in 15%
of patients, including behavioral changes and progressive
intellectual deterioration with [43–45] or without seizures
[46].
5. Neuroimaging
Computedtomography(CT)andmagneticresonance(MRI)
studies have shown central nervous system abnormalities
in LScs patients. Neurologic ﬁndings are more frequently
ispilateral to the skin lesions, but contralateral involvement
has been described [19, 36]. Neurologic symptoms should
not be used as a predictor for MRI abnormalities because
neurologic lesions have been discovered in asymptomatic
patients [30, 47]. Moreover, symptomatic patients were
sometimes proven to have normal radiologic exams.
Outer diploe thinning, cerebral atrophy, white matter
lesions, focal subcortical calciﬁcations, and meningocortical
alterations have been described [30, 35]. Intraparenchymal
calciﬁcations involving basal ganglia, thalami, and dentate
nucleiarethemostcommonbrainlesioninLScspatients[30,
47, 48]. Characteristically, the calciﬁcations are ipsilateral
[46, 49], but contralateral involvement may occur [36, 50].
MRI usually exhibits T2 hyperintensities, mostly in
subcortical white matter, but also in corpus callosum, deep
grey nuclei, and brain stem [29, 30, 40, 46, 47, 51, 52].
Cerebral atrophy is generally subtle, characterized by
blurring of the gray-white interface, cortical thickening, and
abnormal gyral pattern [30]. Atrophy is usually focal but
widespread lesions involving an entire cerebral hemisphere
have been described [30, 46, 52]. Hippocampal atrophy is
unusual, but has been reported [28, 35]. Infratentorial
lesionsandcerebellarhemiatrophyhavebeenobservedinpa-
tients presenting more severe neurological symptoms [27].
Cerebral angiograms and magnetic resonance angiog-
rams studies showed vascular involvement suggestive of vas-
culitis. Reports of cerebral aneurysms and other vascular
malformations, as brain cavernomas [48, 53, 54], exist and
could represent late sequelae of vasculitic process.
6. Treatment
At this moment, no randomized controlled trials exist for
LScs. In a retrospective study of LScs and/or PRS patients4 Autoimmune Diseases
conducted at a tertiary care center, antimalarials, methotrex-
ate, topical and oral steroids, and tetracycline were used
for cutaneous disease, but no deﬁnite conclusions could be
drawn due to the small sample size and the absence of a
control group [55]. D-penicillamine, methylprednisolone,
mycophenolate mofetil, and methotrexate might be con-
sidered in the treatment of neurologic involvement of
LScs [9]. In reported cases, association of methotrexate or
mycophenolate mofetil and steroids appeared to have impact
in controlling intractable seizures and stabilizing central
nervous system damage [27, 40, 44, 48, 56].
7. Conclusion
Once believed to exclusively involve skin, subcutaneous tis-
sue, and bone, LS has been associated to systemic symptoms.
Rheumatologic, ophthalmologic, and neurologic manifesta-
tions seem to be present in around 20% of the patients, and,
in those with LScs, nervous system disorders are the most
prevalent extracutaneous presentation.
Neurologic damage in LScs is frequent and independent
of clinical signs and symptoms. Radiologic ﬁndings and
pathologic studies point towards a neurovasculitic hypothe-
sis. The investigations of choice are CT, to detect skull abnor-
malities, and MRI, to identify underlying brain lesions. Neu-
roimaging studies should be considered in all LScs patients
at the time of the diagnosis. Longitudinal studies should be
donetoidentifyprogression,eveninasymptomaticpatients.
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